200 related articles for article (PubMed ID: 32381573)
21. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
Vijenthira A; Chan K; Cheung MC; Prica A
Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma.
Steidl C; Diepstra A; Lee T; Chan FC; Farinha P; Tan K; Telenius A; Barclay L; Shah SP; Connors JM; van den Berg A; Gascoyne RD
Blood; 2012 Oct; 120(17):3530-40. PubMed ID: 22955918
[TBL] [Abstract][Full Text] [Related]
23. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium.
Rodday AM; Parsons SK; Upshaw JN; Friedberg JW; Gallamini A; Hawkes E; Hodgson D; Johnson P; Link BK; Mou E; Savage KJ; Zinzani PL; Maurer M; Evens AM
J Clin Oncol; 2023 Apr; 41(11):2076-2086. PubMed ID: 36495588
[TBL] [Abstract][Full Text] [Related]
24. Clinico-pathological significance of immunohistochemically marked tumor-associated macrophage in classic Hodgkin lymphoma.
Abd Allah MYY; Fahmi MW; El-Ashwah S
J Egypt Natl Canc Inst; 2020 Apr; 32(1):18. PubMed ID: 32372254
[TBL] [Abstract][Full Text] [Related]
25. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
26. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study.
Belada D; Štěpánková P; Sýkorová A; Žák P; Smolej L
Leuk Lymphoma; 2015 Jul; 56(7):2013-8. PubMed ID: 25330440
[TBL] [Abstract][Full Text] [Related]
27. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
Borchmann P; Haverkamp H; Diehl V; Cerny T; Markova J; Ho AD; Eich HT; Mueller-Hermelink HK; Kanz L; Greil R; Rank A; Paulus U; Smardova L; Huber C; Dörken B; Nerl C; Krause SW; Mueller RP; Fuchs M; Engert A
J Clin Oncol; 2011 Nov; 29(32):4234-42. PubMed ID: 21990399
[TBL] [Abstract][Full Text] [Related]
28. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.
Spina V; Bruscaggin A; Cuccaro A; Martini M; Di Trani M; Forestieri G; Manzoni M; Condoluci A; Arribas A; Terzi-Di-Bergamo L; Locatelli SL; Cupelli E; Ceriani L; Moccia AA; Stathis A; Nassi L; Deambrogi C; Diop F; Guidetti F; Cocomazzi A; Annunziata S; Rufini V; Giordano A; Neri A; Boldorini R; Gerber B; Bertoni F; Ghielmini M; Stüssi G; Santoro A; Cavalli F; Zucca E; Larocca LM; Gaidano G; Hohaus S; Carlo-Stella C; Rossi D
Blood; 2018 May; 131(22):2413-2425. PubMed ID: 29449275
[TBL] [Abstract][Full Text] [Related]
29. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.
Chan TSY; Hwang YY; Khong PL; Leung AYH; Chim CS; Tse EWC; Kwong YL
Hematol Oncol; 2020 Dec; 38(5):726-736. PubMed ID: 32786092
[TBL] [Abstract][Full Text] [Related]
30. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).
Sieniawski M; Reineke T; Nogova L; Josting A; Pfistner B; Diehl V; Engert A
Blood; 2008 Jan; 111(1):71-6. PubMed ID: 17890456
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma.
Guo B; Cen H; Tan X; Ke Q
BMC Med; 2016 Oct; 14(1):159. PubMed ID: 27745550
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases.
Kubes V; Kren L; Sokol F; Michalka J; Muzik J; Arpas T; Krenova Z; Kral Z
In Vivo; 2023; 37(4):1735-1742. PubMed ID: 37369476
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
[TBL] [Abstract][Full Text] [Related]
34. Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study.
Biccler JL; Glimelius I; Eloranta S; Smeland KB; Brown PN; Jakobsen LH; Frederiksen H; Jerkeman M; Fosså A; Andersson TML; Holte H; Bøgsted M; El-Galaly TC; Smedby KE
J Clin Oncol; 2019 Mar; 37(9):703-713. PubMed ID: 30726176
[TBL] [Abstract][Full Text] [Related]
35. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients.
Karihtala K; Leivonen SK; Karjalainen-Lindsberg ML; Chan FC; Steidl C; Pellinen T; Leppä S
Blood Adv; 2022 Mar; 6(6):1919-1931. PubMed ID: 34941990
[TBL] [Abstract][Full Text] [Related]
36. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.
Montanari F; Diefenbach CS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):518-24. PubMed ID: 26351815
[TBL] [Abstract][Full Text] [Related]
37. Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.
Nogová L; Reineke T; Josting A; Müller-Hermelink HK; Eich HT; Behringer K; Müller RP; Diehl V; Engert A
Eur J Haematol Suppl; 2005 Jul; (66):106-10. PubMed ID: 16007877
[TBL] [Abstract][Full Text] [Related]
38. [Microenvironment in classical Hodgkin lymphoma].
Mottok A
Pathologe; 2020 May; 41(3):254-260. PubMed ID: 32239325
[TBL] [Abstract][Full Text] [Related]
39. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
[TBL] [Abstract][Full Text] [Related]
40. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.
Rodig SJ; Ouyang J; Juszczynski P; Currie T; Law K; Neuberg DS; Rabinovich GA; Shipp MA; Kutok JL
Clin Cancer Res; 2008 Jun; 14(11):3338-44. PubMed ID: 18519761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
